Verition Fund Management
IMNM icon

Verition Fund Management’s Immunome IMNM Stock Holding History

Verition Fund Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-72,864
Closed -$1.57M – 2898
2025
Q4 		$1.57M Buy
+72,864
New +$1.28M 0.01% 1813
2025
Q3 		– Sell
-12,875
Closed -$120K – 3879
2025
Q2 		$120K Buy
+12,875
New +$106K ﹤0.01% 3457
2025
Q1 		– Sell
-11,175
Closed -$119K – 3502
2024
Q4 		$119K Buy
+11,175
New +$135K ﹤0.01% 3064

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Verition Fund Management's IMNM Position: Q1 2026 in Review

Verition Fund Management sold out of Immunome (IMNM) in Q1 2026, closing a stake of 72,864 shares — an estimated $1.57M sold.

Verition Fund Management first reported a position in IMNM in Q4 2024 and held it in 3 quarters. The position peaked at $1.57M in Q4 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Verition Fund Management reported no remaining Immunome position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 72,864 Immunome shares in Q1 2026, an estimated $1.57M.
  • Verition Fund Management first reported a position in Immunome in Q4 2024 and held it in 3 quarters.
  • Verition Fund Management's Immunome position peaked at $1.57M in Q4 2025.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.